perflexane
Trade name: Imagent
Approved
May 31, 2002
Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure. Commercially available contrast media are gas-filled microbubbles that are administered intravenously to the systemic circulation. Microbubbles have a high degree of echogenicity. There is a great difference in echogenicity between the gas in the microbubbles and the soft tissue surroundings of the body. Thus, ultrasonic imaging using microbubble contrast agents enhances the ultrasound backscatter, (reflection) of the ultrasound waves, to produce a sonogram with increased contrast due to the high echogenicity difference. Contrast-enhanced ultrasound can be used to image blood perfusion in organs, measure blood flow rate in the heart and other organs, and for other applications. — Wikipedia
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Timeline
1990s
- Aug 13, 1993
Alliance Pharmaceutical Corp. — First NDA Organization
- Aug 13, 1993
Alliance Pharmaceutical Corp. — NDA Organization
2000s
- May 31, 2002
Earliest FDA Approval
- May 31, 2002
Vesselon Spv Llc — NDA Secondary Org
Indications
Approved for
Mechanism of action
- contrast mediumRadiopaque
contrast medium radiopaque
Combination products
imagent
with dimyristoyl lecithin
Approval history
- approvedMay 31, 2002
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaContrast-enhanced ultrasound ↗
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alliance Pharmaceutical Corp. | For profit | NDA | Aug 13, 1993 |
| Vesselon Spv Llc | For profit | NDA2 | May 31, 2002 |